Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma

This article was originally published in PharmAsia News

Executive Summary

Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.


Related Content

With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs
After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts